SAN JOSE, Calif., April 23, 2018 -- According to the latest report published by Credence Research, Inc. “Post-Traumatic Stress Disorder Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2018-2026,” the global post-traumatic stress disorder therapeutics market is projected to reach US$ 10,679.5 Mn by 2026, expanding at a CAGR of 4.5% from 2018 to 2026.
Market Insights
Post-traumatic stress disorder (PTSD) therapeutics market projected to an extent by US$ 10,679.5 Mn by 2026 with a CAGR of 4.5% throughout the forecast period from 2018 to 2026. Antidepressants are the class of promising drugs that play a stellar role in the market. Global post-traumatic stress disorder therapeutics market from 2018 to 2026 has been prepared based on exhaustive analysis with insights from industry professionals. The detailed study incorporates the market landscape and its growth scenarios for the forecast period from 2018 to 2026. To estimate the market size, the report ruminates branded, generic and pipeline drugs.
As per the U.S. National Comorbidity Survey Replication, around 6.8% individuals experience the ill effects of PTSD. As indicated by PTSD United, Inc. around 70% of individuals in the United States has encountered a few sorts of the shocking accident in any event once in their lives. This associate to around 223.4 million individuals. The usage rate of healthcare services is highest in case of individuals suffering from PTSD. There are various symptoms that are commonly grouped into four different types: avoidance, changes in physical and emotional reactions, negative changes in thinking and mood, and intrusive memories that are identified in the individuals having post-traumatic stress disorder.
Based on the class of drug, the global post-traumatic stress disorder therapeutics market is segmented into antidepressants, anti-anxiety drugs, other drug classes (Alpha-1 & Alpha-2 Receptor Antagonists, Atypical Antipsychotics, and Anticonvulsants), and pipeline candidates. Rising prevalence of PTSD and the promising drug pipeline would additionally boost the post-traumatic stress disorder therapeutics market.
Geographically, the overall post-traumatic stress disorder therapeutics market is projected for the Middle East and Africa, Europe, North America, Latin America, and the Asia Pacific. North America currently drives the global market and projected to hold its supremacy throughout the forecast period. However, Europe will be clearly challenged by the Asia Pacific by end of the forecast period. The need for post-traumatic stress disorder therapeutics drugs has become prominent in the Asia Pacific because of rapidly increasing events such as sexual assault, combats and inter-personal violence. There are massive chances for market penetration in countries like China, and India by the market leaders who at present have a stronghold in developed countries.
Browse Full Report With TOC, Figures And Tables @ http://www.credenceresearch.com/report/post-traumatic-stress-disorder-therapeutics-market
Related Reports:
Cytomegalovirus (CMV) Infection Treatment Market
Acquired Hemophilia Treatment Market
About Us:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.
Contact:
Name: Chris Smith
Designation: Global Sales Manager
E-mail: [email protected]
Ph: +1-800-361-8290
Connect With US:
Web: Credence Research
Facebook @ https://www.facebook.com/CredenceResearch
Twitter @ https://twitter.com/CredenceResearc
LinkedIn @ https://us.linkedin.com/company/credenceresearch
G+ @ https://plus.google.com/+Credenceresearch


Tesla Raises Cybertruck Prices by $5,000 in US
Google Expands Gemini Enterprise With AI Tools for Legal Sector
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny
Yindjibarndi Appeals Fortescue Mining Compensation Ruling
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7%
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook
Nvidia Options Price in $280 Billion Earnings Swing
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing
Mercer International Stock Surges 45% on C$20 Million Canada Funding
SK Hynix Shares Fall as Workers Reject Wage Deal
Bathla Group Hires Administrators as Australia Housing Slump Deepens
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14%
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 



